Age1

Emerging manager

Built from this firm's Form D filings. The firm files no SEC adviser report.

Website: https://age1.com
HQ: CA

Age1 is a venture firm that backs contrarian founders building generational biotech companies aimed at extending healthy lifespan, starting at the earliest stage. Its team includes co-founders Alex Colville and Laura Deming, along with partners, associates, and fellows.

New fund likely raising soon

The firm's newest fund is 4 to 7 years past its first sale and no newer Form D has been filed.

01 · Says / Does

Tag	Says	Does
Stages	Pre-seed, Seed, Series A	Not enough dated deals
Sectors	Biotech	Not enough dated deals
Regions	Global	Not enough dated deals

Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.

02 · Fund history

Fund	Year	Size	Status
age1 Fund I, LP age1 invests at the earliest stage, often before any money has been raised, in contrarian founders building biotech companies. It backs therapeutics, tools, and technologies targeting aging and age-related disease to extend healthy lifespan. Inferred from the firm's website	2022	$55M (Form D)	Late investment period

03 · People across funds

Alex Colville, Managing Member of the General Partner of the Issuer
age1 Fund I, LP (Named on Form D)
Carol Magalhaes, NewCo Chief of Staff
age1 Fund I, LP (Team)
Doug Henze, Venture Fellow
age1 Fund I, LP (Team)
Ezekiel Bajomo, Venture Fellow
age1 Fund I, LP (Team)
Laura Deming, Co-Founder, Venture Partner
age1 Fund I, LP (Team)
Madi Ueland, Senior Associate
age1 Fund I, LP (Team)
Maggie Li, Special Projects Lead
age1 Fund I, LP (Team)
Satvik Dasariraju, Partner
age1 Fund I, LP (Team)

04 · Recent deals

No dated deals found yet.

05 · Latest from the firm

No news from the firm's website yet.

06 · Sources

Fund dates and sizes are from SEC Form D filings.

Last verified: Oct 28, 2026